This healthcare platform offers a non-invasive device to continuously measure blood glucose in preterm infants. By collecting glucose found on the skin, the device allows healthcare providers to safely monitor blood glucose concentrations without traditional blood draws.
Funding
Funding not disclosed
Founders
Product
Problem
Frequent blood draws to measure blood glucose concentration in preterm infants can cause pain, stress, and potential complications such as anemia. Current methods are invasive and do not provide continuous monitoring, making it difficult to detect and respond to rapid fluctuations in glucose levels that can lead to brain damage and lifelong disabilities.
Solution
Gluckli is developing a non-invasive medical device that continuously measures blood glucose concentration (BGC) in very- and extremely preterm infants. The device collects glucose found on the skin, eliminating the need for repeated blood sampling. This continuous monitoring allows healthcare providers to safely and effectively track BGC levels, enabling timely intervention to prevent hypoglycemia and associated neurological damage. The technology aims to replace invasive blood sampling, offering a safer and more comfortable monitoring solution for vulnerable infants.
Target Audience
The primary target audience includes neonatologists, nurses, and other healthcare providers in neonatal intensive care units (NICUs) who monitor and manage blood glucose levels in preterm infants.
Features
- Non-invasive glucose monitoring via skin contact
- Continuous measurement of blood glucose concentration (BGC)
- Real-time data transmission to enable timely intervention
- Designed specifically for very- and extremely preterm infants
- Aims to replace invasive blood sampling methods